

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Akesobio**

**Akeso, Inc.**

**康方生物科技(開曼)有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9926)**

## **VOLUNTARY ANNOUNCEMENT**

### **INCLUSION OF THE SHARES OF THE COMPANY AS A CONSTITUENT STOCK OF 13 HANG SENG INDEX SERIES, INCLUDING HANG SENG COMPOSITE INDEX AND HANG SENG STOCK CONNECT HONG KONG INDEX**

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, based on quarterly review on Hang Seng Index Series announced by Hang Seng Indexes Company on August 14, 2020, the Company will be selected as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from September 7, 2020:

- (1) Hang Seng Composite Index (“**HSCI**”)
- (2) Hang Seng Stock Connect Hong Kong Index
- (3) Hang Seng Hong Kong-Listed Biotech Index
- (4) Hang Seng SCHK New Economy Index
- (5) Hang Seng Healthcare Index

- (6) Stock Connect Greater Bay Area Composite Index
- (7) Hang Seng SCHK ex-AH Companies Index
- (8) Hang Seng SCHK HK Companies Index
- (9) Hang Seng Stock Connect Greater Bay Area Macao-Zhuhai-Zhongshan-Jiangmen Index
- (10) Hang Seng Large-Mid Cap Value Tilt Index
- (11) Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
- (12) Hang Seng Stock Connect Greater Bay Area Consumer Goods Index
- (13) Hang Seng Stock Connect Greater Bay Area New Economy Index

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95<sup>th</sup> percentile of the total market capitalisation of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Adopting the freefloat-adjusted market capitalisation methodology, the Hang Seng Composite Index can be used as a basis for index funds, mutual funds as well as performance benchmarks. The Hang Seng Hong Kong-Listed Biotech Index reflects the overall performance of the biotech companies that are listed in Hong Kong, including stocks listed on the Stock Exchange through Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Hang Seng Healthcare Index aims to reflect the overall performance of stocks listed in Hong Kong that are related to healthcare businesses.

## **INFORMATION ABOUT THE COMPANY**

Akeso, Inc. (HKEX stock code: 9926.HK) is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. Since the Company’s establishment, the Company has established an comprehensive end-to-end drug development platform (ACE Platform) and system, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC process development, and GMP-compliant commercial scale manufacturing. The Company has also successfully established a bi-specific antibody drug development technology (Tetrabody technology). The Company currently has a pipeline of over 20 innovative investigative

drugs for the treatment of major diseases like cancer, autoimmune diseases, inflammation and metabolic diseases, 9 of which have entered clinical stage, including two novel first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). Akeso, Inc.'s vision is to become a global leading biopharmaceutical company through efficient and break-through research and development in innovating and developing new drugs that are first-in-class and best-in-class therapies.

By Order of the Board

**Akeso, Inc.**

**Dr. XIA Yu**

*Chairwoman and executive director*

Hong Kong, August 18, 2020

*As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Mr. LIN Lijun and Dr. ZHOU Yi as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.*